Source:http://linkedlifedata.com/resource/pubmed/id/19377516
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2009-12-9
|
| pubmed:abstractText |
The aim of this study was to investigate the effects of natural killer (NK) cells on transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Forty-one haploidentical allogeneic hematopoietic SCT patients were analyzed according to the NK cell concentration in relation to acute GVHD (aGVHD), chronic GVHD (cGVHD), TRM and leukemia-free survival. The patients receiving a higher dose of CD56(bright) NK cells (>1.9 x 10(6)/kg) showed a higher incidence of grades II-IV aGVHD (hazard risk (HR), 2.872; P=0.022) and cGVHD (HR, 2.884; P=0.039). A higher CD56(dim)/CD56(bri) NK cell ratio (>8.0) was correlated with a decreased risk of III-IV aGVHD (HR, 0.290; P=0.065) and TRM (HR, 0.072; P=0.012), thereby increasing the rate of leukemia-free survival (HR, 0.174; P=0.007) after haploidentical transplantation without in vitro T-cell depletion. Our results suggest that a high allograft CD56(dim)/CD56(bright) NK cell ratio (>8.0) plays an important role in improving transplant outcomes. A higher dose of CD56(bright) NK cells might be a predictor for a higher incidence of GVHD.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1476-5365
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
721-8
|
| pubmed:meshHeading |
pubmed-meshheading:19377516-Adult,
pubmed-meshheading:19377516-Antigens, CD56,
pubmed-meshheading:19377516-Bone Marrow Cells,
pubmed-meshheading:19377516-Disease-Free Survival,
pubmed-meshheading:19377516-Female,
pubmed-meshheading:19377516-Graft vs Host Disease,
pubmed-meshheading:19377516-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:19377516-HLA Antigens,
pubmed-meshheading:19377516-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:19377516-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19377516-Histocompatibility Testing,
pubmed-meshheading:19377516-Humans,
pubmed-meshheading:19377516-Killer Cells, Natural,
pubmed-meshheading:19377516-Male,
pubmed-meshheading:19377516-Tissue Donors,
pubmed-meshheading:19377516-Transplantation, Homologous,
pubmed-meshheading:19377516-Transplantation Conditioning,
pubmed-meshheading:19377516-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
|
| pubmed:affiliation |
Department of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, no. 11 Xizhimen South Street, Beijing, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|